Invivyd pushes DECLARATION data timeline, names new CEO as PEMGARDA sales rise 18%
Invivyd said Phase 3 data on VYD2311 is now expected imminently after discussions with FDA, as the company reported third-quarter PEMGARDA revenue growth and a leadership change.
Invivyd, Inc. reported on November 16, 2026 that DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) will be available imminently, under the Accelerated Approval analysis and regulatory submission plan previously communicated by the company.1 The company said the updated timing follows dialogue with the FDA aimed at refining the Accelerated Approval approach for VYD2311 and expanding the accelerated regulatory pathway for future Invivyd antibodies, including its measles candidate.1
Invivyd also announced positive topline results from its LIBERTY Phase 3 trial. The company said VYD2311 met all primary and secondary endpoints versus an mRNA-based COVID-19 vaccine, with safety and tolerability that was clinically and statistically superior to the vaccine comparator.1 Separately, combining VYD2311 with the mRNA vaccine showed no interference with vaccine-induced neutralizing titers and instead added to them.1
The company also disclosed initiation of its FLINTLOCK Phase 2 trial, which will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose VYD2311 in adults aged 18-65 with Long COVID or Post-Vaccination Syndrome.1
On the commercial side, PEMGARDA (pemivibart) net product revenue reached $15.4 million for the third quarter, up from $13.1 million a year earlier, an increase the company attributed to increased patient demand.1 Invivyd noted that in July 2026 it received twelve months’ advance notice of emergency use authorization termination for PEMGARDA and is in dialogue with FDA about next steps.1
In a corporate change, Invivyd said Marc Elia, Chairman of the Board, was appointed Chief Executive Officer.1 The company reported cash and cash equivalents of $126.4 million as of September 30, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.